Hasan Alam, MD

Norman W. Thompson Professor of Surgery
Section Head of General Surgery
University of Michigan

Dr. Alam is the Norman Thompson Professor of Surgery and Section Head for the Section of General Surgery at the University of Michigan Hospital. He is an Acute Care Surgeon who is certified by the American Board of Surgery in General Surgery and Surgical Critical Care. He received his surgical training at the Washington Hospital Center in Washington DC, followed by a post-doctoral research fellowship at the Uniformed Services University of Health Sciences (USUHS) in Bethesda, MD. He then served as a faculty member at the Georgetown University as well as USUHS before moving to Boston to join the Massachusetts General Hospital (MGH) in 2005. There he was rapidly promoted to the position of Professor of Surgery at the Harvard Medical School, and served as the Director of Surgical Critical Care Fellowship Program at the MGH. He was also the founding Medical Director of the multi-disciplinary Intensive Care Unit, and chaired the State Committee on Trauma for many years before moving to Ann Arbor in 2012.

Dr. Alam’s clinical interests are in the areas of trauma, emergency general surgery and surgical critical care. His research focuses on hemorrhagic shock, traumatic brain injuries, resuscitation techniques, novel cell preservation strategies, modulation of response to lethal insults, therapeutic hypothermia, hemorrhage control, and development of new treatments for sepsis. This research is funded by large federal grants by the National Institutes of Health as well as by the US Department of Defense. He has published nearly 200 manuscripts and book chapters and is the holder of 6 patents. He has won numerous awards for excellence in teaching and research, and serves on the editorial boards of nearly all of the leading surgical, trauma and critical care journals. He is a member of more than 15 surgical/scientific societies including the American Surgical Association, American Association for the Surgery of Trauma, Society of University Surgeons, and the Society of Clinical Surgery.

Julie Allickson, PhD

Director, Regenerative Medicine Clinical Center
Wake Forest University School of Medicine

Julie Allickson, Director of the Regenerative Medicine Center at Wake Forest Institute for Regenerative Medicine focuses on the translation of regenerative medicine products including cell therapy, tissue engineering, biomaterials and devices. This process begins at Proof-of-Concept where early discussion with regulators and clinicians are critical in moving the technology from the bench to the bedside. The Translational Team includes Quality Assurance, Quality Control, Regulatory Affairs, Process Development and the GMP-complaint Manufacturing Facility. Prior to joining the institute, she was an Executive Officer of the company and Vice President of Laboratory Operations and R & D at Cryo-Cell International, Inc., an AABB accredited Cord Blood Bank.

Anthony Atala, MD

Professor of Surgery
Chair, Department of Urology
Director, Wake Forest Institute for Regenerative Medicine at Wake Forest University

Dr. Anthony Atala, George Link Professor and Director of the Wake Forest Institute for Regenerative Medicine, is a practicing surgeon and a regenerative medicine researcher. His work focuses on growing human tissues and organs using cells and 3D Printing. He is Editor-in-Chief of three journals. He is a National Academy of Medicine and National Academy of Inventors member. His work has been listed twice as Time Magazine’s top 5 medical breakthroughs of the year and he was named by Scientific American as one of the world’s most influential people in biotechnology. He has received numerous awards for his work, including the Edison Science Award, the Smithsonian Ingenuity Award, and the R&D Innovator of the Year Award. More than 14 applications of his laboratory technologies have been used clinically. He is the editor of 20 books, has published over 600 journal articles, and has applied/received over 250 national and international patents.

Priya Baraniak, PhD

Vice President, Corporate Development
OrganaBio, LLC

Dr. Baraniak, Vice President of Corporate Development at OrganaBio LLC, is a proven strategic thinker, problem solver and leader with 20 years of experience in stem cells and tissue engineering, coupled with a keen business acumen. Priya has published multiple peer-reviewed papers and book chapters on the use of stem cells and biomaterials in cardiac repair and regeneration and is routinely invited to speak at conferences. Before joining OrganaBio, Priya was a founding member of RoosterBio and was a vital member of the company’s Leadership Team. Priya’s industry experience also includes a role as Senior Director of R&D for Garnet BioTherapeutics, a clinical-stage stem cell-based regenerative medicine company, where Priya led multiple projects on tissue repair and regeneration using mesenchymal stem cell (MSC)-based therapeutics and devices.

Priya’s holds a Bachelor of Science in Engineering (BSE) from Duke University in Electrical Engineering and Biomedical Engineering. While at Duke, Priya conducted research in the lab of Dr. Doris A. Taylor on cardiac repair and regeneration. Priya went on to receive her Ph.D. in Bioengineering from the University of Pittsburgh, completing her dissertation research in the laboratory of Dr. William R. Wagner working on biodegradable elastomer applications in cardiovascular regenerative medicine. Her post-doctoral research in Dr. Todd McDevitt’s lab in the Department of Biomedical Engineering at Georgia Tech and Emory University as an American Heart Association Fellow focused on harnessing the secretome and isolating the extracellular matrix from MSCs and other cell types, including pluripotent stem cells, for cardiac tissue repair and regeneration.  Priya co-authored many grants while a post-doc and went on to contribute critical sections to a NIST grant that resulted in the first ever National Cell Manufacturing Consortium in the United States. In her current role at OrganaBio, Priya continues to participate in numerous cell manufacturing and regenerative medicine initiatives to deliver on her personal mission of advancing therapies to the clinic, benefitting patients.

Kenneth Bertram, MD, PhD

COL, USA, Ret.
Professor of Regenerative Medicine
Wakeforest University

Bertram is also board certified in Internal Medicine and Medical Oncology; a Fellow of the American College of Physicians ; a member of the U.S. Army Acquisition Corps, Acquisition Level III certified in both Program Management and Science and Technology Management; and his military honors include two Legion of Merit awards, The Surgeon General’s “A” Proficiency Designator in Hematology/Oncology and the Order of Military Medical Merit.

Karim Brohi, MD

Professor of Trauma Sciences
Queen Mary University of London
Director London Major Trauma System

I am a trauma and vascular surgeon with a strong academic focus in translational and clinical research into acute injury care.

My trauma surgery practice is based at the Royal London Major Trauma Centre, part of Barts Health NHS Trust and one of the busiest trauma centres in Europe managing severely injured patients from across metropolitan London.

My trauma research at Queen Mary University of London focuses around the immediate minutes and hours after injury – and how understanding the pathophysiology of this time can produce innovations in therapeutics and device interventions to save lives. We have an international reputation for our work in traumatic coagulopathy and massive transfusion, inflammation and organ dysfunction. Vital to this is improving the quality of life for our new survivors, and we also research into trauma rehabilitation and systems of care. The Centre for Trauma Science web site is at www.c4ts.qmul.ac.uk and www.aftertrauma.org for patients and families.

I am Clinical Director for Major Trauma for London and chair the Major Trauma steering group of the four London major trauma operational delivery networks. The London Major trauma system is the largest integrated urban trauma system in the world, managing over 12,000 injuries a year. We ensure high quality and equity of care across the area of London and the South East that we serve, and use the scale and expertise of the London Major trauma system to innovate across patient care pathways. More at www.londontraumasystem.org.

I act as medical expert witness, especially in cases of severe or complex personal injury. I also act in clinical negligence cases for trauma and vascular cases.

Andrew (Andre) Cap, MD, PhD

Professor of Medicine
Uniformed Services University of the Health Sciences
Chief, Blood Research Program
US Army Institute for Surgical Research

Dr. Cap is a hematologist conducting basic and translational research on coagulation system function and cellular therapy products for use in trauma and burn care. His mission is to lead the US Army Institute of Surgical Research Coagulation and Blood Research Group. He also serves as a staff Hematologist-Oncologist at the San Antonio Military Medical Center (SAMMC), as a core faculty member its Hematology-Oncology Fellowship Program, as Program Director for the Clinical Investigation Fellowship Program and as an Associate Professor of Medicine at the Uniformed Services University. He is a board certified internist and hematologist-oncologist and serves as hematology and blood products subject matter expert advisor to the Joint Trauma System (JTS), US Pacific Command, and the US Special Operations Command (SOCOM).

His overall research goals are to decrease battlefield mortality, with emphasis on providing diagnostic and therapeutic interventions to treat hemorrhage and the coagulopathy of trauma. The mission of the Blood and Coagulation program has been focused on defining the pathophysiologic effects of trauma on the coagulation system. Specifically, they are analyzing new diagnostics and interventions to understand the role of platelets, cell-derived microparticles, and transfusion strategies in prevention or creation of clots that occur in trauma and burned soldiers. Their goal is to improve storage, preparation, and efficacy of blood products delivered to the far-forward battlefield.

Becky Cap

Sr. Vice President, Chief Operating Officer, GenCure

Becky Cap, a 20-year veteran of the life sciences industry, was named chief operating officer of San Antonio-based GenCure in February, 2016. GenCure, a subsidiary of BioBridge Global, is focused on providing and developing regenerative medicine and cellular therapy products. GenCure’s mission is to realize the potential of donated human cells and tissue to save and enhance lives.

Cap, a native of Texas, earned a bachelor’s degree from Harvard University. She began her career at Dana-Farber Cancer Institute in Boston, where she gained clinical, laboratory and regulatory experience. She developed her foundational knowledge of clinical medicine in the context of managing clinical trials focused on exploring the benefits of hematologic stem cell transplant for breast cancer and the effects of growth factors in high-dose chemotherapy trials.

While pursuing her MBA at Boston University’s Health Care Management Program, she moved to industry and began working for Eidetics, a consulting firm focused on informing biomedical product development support.  She supported US and global development and strategic marketing efforts for chemotherapeutics, leading monoclonal antibodies, tyrosine kinase inhibitors and bio-oncology agents, including PD-1 and PDL-1 inhibitors.  Her expertise was honed as Oncology became an active and competitive “market” in which physicians and patients had multiple treatment options available to them for their cancers.  Hers was one of the first Oncology Consulting Practices in this strategic marketing and market research space.  She also has run her own consulting firm and worked with a number of local startups in the San Antonio community.

Cap has provided strategic guidance for the development of pharmaceuticals and medical devices, both in large, established firms and early stage ventures.  She has provided extensive entrepreneurial coaching. She is an active member of local and national committees on Regenerative Medicine and Cell Therapy, two private company Boards of Directors and the Governing Committee for Seton Home. Additionally, Cap is a co-founder and founding president of San Antonio TechBoosters, a 501(c)6 organization established to mentor student entrepreneurs.

David Chang, MD, PhD

CEO and President, Allogene Therapeutics Inc.

Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Co-Founder and Director of Allogene Therapeutics, Inc. serves as Scientific Advisory Board Member of Kronos Bio, Inc. He is a Venture Partner at Two River and previously served as Executive Vice President, Research & Development, and Chief Medical Officer of Kite, a Gilead Company. He serves as a Director at A2 Biotherapeutics and Peloton Biotherapeutics, and a Venture Partner at Vida Ventures. He has an industry-leading track record of innovation in the field of oncology drug development, including the development for Yescarta™ (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma. From 2002 to 2014, he held senior leadership roles at Amgen, including Vice President of Global Development and Head of Hematology-Oncology. During this time, He spearheaded personalized therapy strategies that underlied the success of Vectibix® (panitumumab). He also provided therapeutic area leadership to pivotal programs for Blincyto® (blinatumomab) a bispecific T cell engager antibody in acute lymphocytic leukemia and for IMLYGIC™ (talimogene laherparepvec) a first-of-its-kind oncolytic immunotherapy, in melanoma. Prior to joining Amgen, he held dual appointments as Associate Professor of Medicine and of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He is on the board of Peloton Therapeutics and scientific advisory board to Kronos Bio. He obtained a B.S. degree in Biology from the Massachusetts Institute of Technology and M.D. and Ph.D. degrees from Stanford University. He completed an internship and residency in internal medicine at Brigham and Women’s Hospital and a fellowship in medical oncology at Dana-Farber Cancer Institute at Harvard Medical School, where he was a Howard Hughes Medical Institute postdoctoral fellow.

Donna Chang, PhD

President & CEO
Hope Biosciences

Donna Chang has over 12 years of experience in biotechnology business development, including business expansion and strategic partnering. Donna started her career with the Maryland Department of Business Economic Development, attracting life science companies to the State. Her duties included vetting and negotiating with companies to locate their resources within the State. Her primary responsibility was to ensure that the biotechnologies that came into the State had a high economic development impact and could positively impact the community. Her last recruit was an Asian based stem cell company and shortly after, she transitioned into the stem cell industry. Since 2007 Donna has served as an executive in commercial stem cell companies and headed up regulatory and marketing activities and facilitated research and partnering agreements. Donna graduated from the University of Toronto with a degree in Bioethics and Human Biology. She received her Masters (M.S.) in Biotechnology with a concentration in Enterprise Development from Johns Hopkins University.

Joseph Ciacci, MD

Professor of Neurosurgery
Vice Chair of Research
University of California San Diego

Joseph Ciacci, MD, is a board-certified neurosurgeon with extensive experience in neuro-oncology of the spine and brain. Dr. Ciacci’s primary interests are tumors of the spine and brain, complex spinal reconstruction, and stereotactic radiosurgery, a form of radiation therapy that focuses high-power energy on a small area of the body.

As a professor in the Department of Surgery, Dr. Ciacci instructs medical students, residents and fellows at UC San Diego School of Medicine. He also directs the Neurosurgery Residency Program.

Dr. Ciacci was on the faculty at the Johns Hopkins School of Medicine for nine years prior to joining the faculty at UC San Diego Health. He also has been a visiting professor and delivered lectures throughout the U.S. and internationally.

He completed neuro-oncology fellowships at UCLA and the National Institutes of Health, completed his residency at Northwestern Memorial Hospital in Chicago, and interned at Mount Sinai School of Medicine in New York. He earned his medical degree from University of Buffalo, SUNY School of Medicine and Biomedical Sciences. He is board certified in neurological surgery.

Larry Corash, MD

Senior VP and Chief Scientific Officer Cerus Inc.

Dr. Corash, a co-founder of Cerus, was appointed as our Chief Scientific Officer in 2009. He has held various medical positions within the company, including Chief Medical Officer from 1994-2015. Dr. Corash was a consultant to us from 1991 to 1994. He has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985 and was Chief of the Hematology Laboratory for the Medical Center at the University of California, San Francisco from 1982 to 1997. From February 1990 to July 1994, Dr. Corash was a consultant to the FDA Advisory Panel for Hematology Devices. He currently serves on the U.S. Health and Human Services’ Advisory Committee on Blood Safety and Availability.

Charles Cox, MD

The George and Cynthia Mitchell Distinguished Chair in Neurosciences
Director, Children’s Program in Regenerative Medicine
Professor, Department of Pediatric Surgery
McGovern Medical School at UTHealth

Dr. Charles S. Cox, Jr., is Professor of Pediatric Surgery, and the George and Cynthia Mitchell Distinguished Chair in Neuroscience, directing the Pediatric Surgical Translational Laboratories and Pediatric Program in Regenerative Medicine at the University of Texas Medical School at Houston. He served in Afghanistan with the 82nd Airborne in the 909th Forward Surgical Team in 2002.The Pediatric Translational Laboratories and Pediatric Program in Regenerative Medicine is a multi-disciplinary effort that addresses problems that originate with traumatic injury and the consequences of resuscitation and critical care. The Program focuses on progenitor cell based therapy (stem cells) for traumatic brain injury, and related neurological injuries (hypoxic-ischemic encephalopathy, stroke, spinal cord injury), recently completing the first acute, autologous cell therapy treatment Phase I study for traumatic brain injury in children (Neurosurgery, 2011). Recently, the NIH funded the first Phase II clinical trial for cellular therapies in children with severe TBI. Three subsequent INDs have been approved for cell-based therapies for neurological injury. The program also develops novel bio-hybrid organs using cell-based and tissue engineering approaches to trauma and injury related problems. These efforts have recently resulted in two IND based cell therapeutic studies, and three patents in the past two years. The program is funded through the National Institutes of Health, Texas Higher Education Coordinating Board/Emerging Technology Funds, Industry Collaboration, and philanthropic contributions. The Program is housed in state-of-the-art laboratory facilities (4500 sf), and includes two cGMP facilities for the production of clinical grade cell and tissue products: Hoffberger Cellular Therapeutics Laboratory and the Griffin Stem Cell Therapeutics Research Laboratory. Other major areas of interest include: (1) resuscitation induced organ edema and dysfunction, (2) the neuroinflammatory reflex, (3) mesenchymal stromal cell exosomes as anti-inflammatory agents, and (4) mechanotransduction of stem cells to enhance their anti-inflammatory properties.

Erika Davies, PhD

Health Scientist
Division of Chemical, Biological, Radiological, and Nuclear Countermeasures (DBRN)
Biomedical Advanced Research and Development Authority (BARDA)

Dr. Erika Davies is a health scientist in the Radiation and Nuclear Medical Countermeasures Branch at the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR). She received her doctorate from the Uniformed Services University of the Health Sciences (USUHS) in Emerging Infectious Diseases in 2007, followed by a post-doctoral fellowship in the Laboratory of Parasitic Diseases (LPD) at the National Institute of Allergy and Infectious Disease (NIAID). Dr. Davies transitioned to science policy and administration as a 2010-2012 AAAS Science and Technology Policy Fellow and has worked for the US government and non-profit organizations to drive scientific research and development activities in infectious disease, women’s health, publishing ethics, radiation biology and drug development.

Michael Davis, MD, FACS

Director of the US Army Medical Research and Materiel Command’s Combat Casualty Care Research Program (CCCRP)

Col Davis grew up in Southern California and did his undergraduate studies at the University of California, Santa Barbara.  He then began his military career when he entered medical school at the Uniformed Services University of the Health Sciences in Bethesda, MD (US Federal Medical School).  Following medical school Col Davis entered General Surgery training at Wilford Hall Medical Center, Lackland AFB, TX.  While in general surgery training, Col Davis performed a 2 year vascular surgery research fellowship.  Following General Surgery training, Col Davis matriculated into Plastic and Reconstructive Surgery training at the University of Alabama at Birmingham School of Medicine.

Col Davis is a member of multiple medical societies including the American College of Surgeons and the American Society of Plastic Surgeons.  He is board certified in both General Surgery/Trauma and Plastic and Reconstructive Surgery.  He was elected a Fellow of the American College of Surgeons in 2010.

Col Davis has deployed in support of Operation Enduring Freedom in Afghanistan where he served as Chief, Reconstructive Surgery.  Following deployment, Col Davis transferred to the US Army Institute of Surgical Research in San Antonio, TX on Special Authorization from the Air Force Surgeon General to begin research in advanced reconstructive surgery and regenerative medicine for the benefit of combat injured.  In 2013, Col Davis became Deputy Commander of the US Army Institute of Surgical Research and began the RESTOR™ program (Restorative Endeavor for Servicemembers Through Optimization of Reconstruction).

Col Davis has served as the Chair of the Scientific Steering Committee for the US Regenerative Medicine Research Portfolio and is currently the Director, US Combat Casualty Care Research Program.

Allan Doctor, MD

Professor of Pediatrics, Biochemistry and Bioengineering
Director, Center for Blood Oxygen Transport and Hemostasis
University of Maryland School of Medicine

Allan Doctor, MD is Professor of Pediatrics, Biochemistry & Bioengineering at the University of Maryland School of Medicine, where he directs the Center for Blood Oxygen Transport and Hemostasis. He is a Pediatric Intensivist and previously led Pediatric Critical Care at Washington University and St Louis Children’s Hospital for 10 years, stepping down and then transitioning to UMB to focus on a rapidly expanding research program and on development of a novel bio-synthetic artificial red cell. His laboratory studies the role of red blood cell-based signaling in the control of regional blood flow, related pathophysiology arising from acquired red cell injuries, blood substitute design, and on translational transfusion medicine in critical illness.

Jonathan Esensten, MD, PhD

Medical Director, UCSF HICTF and GMP Facility Medical Director,
Zuckerberg San Francisco General Hospital Blood Bank and Transfusion
Service Assistant Adjunct Professor, Dept. of Laboratory Medicine

Jonathan Esensten MD, PhD is Assistant Adjunct Professor in the Department of Laboratory Medicine, UCSF. His work is focused on synthetic biology and cellular therapy manufacturing process development. He is co-director of the clinical Regulatory T Cell Manufacturing Group and serves Medical Director of the UCSF HICTF and GMP Facility. He directs the transfusion service at Zuckerberg San Francisco General Hospital. He completed residency in clinical pathology and fellowship in transfusion medicine and blood banking at UCSF.

Mike Fitzpatrick, PhD

COL, USA, Ret.
President & Director of Research and Development, Cellphire Inc.

Dr. Fitzpatrick joined Cellphire in 2006 and leads the company through the development and clinical applications of its first line of products. He has orchestrated the submission and approval of grants or contracts with the Defense Advanced Research Projects Agency, US Army Medical Research and Material Command, and most recently the Biomedical Advanced Research Development Authority. These efforts have funded the preclinical work leading to a successful submission of an IND to FDA for the first in human safety trial of Thrombosomes® a lyophilized platelet derived hemostatic agent. This early Phase 1 IND is scheduled for completion 1st QTR CY2016.

Dr. Fitzpatrick has over 35 years of combined military and civilian experience encompassing all aspects of Blood Services Management. He is a key member of the national and international blood community, influencing clinical practice, regulatory and reimbursement decisions, disaster response procedures, research and development, and strategic planning. Throughout his career, he has been an innovative manager embracing and implementing change in response to the diverse and complex factors that affect blood services such as; regulatory compliance; changes in work force; medical treatment advances; emergent infectious diseases; donor recruitment; clinical practice changes; advances in blood component collection; preparation and storage; cellular therapies; and the development of new therapeutics based on biological and cellular components of blood, bone marrow, or organs.

Prior to joining Cellphire, Dr. Fitzpatrick served as the COO at America’s Blood Centers (ABC) and was in charge of policy and regulatory affairs. He was a key member of the group that developed the AAbb Interorganizational Task Force for Disaster Response and Preparedness at ABC and while in the military.

While serving in the US Army Dr. Fitzpatrick achieved the rank of Colonel. During his military career he served in both technical and operational roles. His last assignment was Director of the Armed Services Blood Program Office (ASBPO) where he developed policy and oversaw the logistics of blood product supply and delivery for the entire Department of Defense. In this role, he also led the effort to introduce advanced products to the military medical community and assisted in their regulatory development. Dr. Fitzpatrick also served as the European Command Blood Program Officer during the first Gulf War and was responsible for planning all blood support for Operations Desert Shield and Desert Storm. When the September 11 attack occurred, he was Director of the ASBPO. Dr. Fitzpatrick planned blood support operations for US combat in Afghanistan and Iraq.

Dr. Fitzpatrick has served in numerous roles on committees for key industry organizations. He was heavily involved with AAbb as in inspector, serving on the Technical Manual and Standards Committees, Dr. Fitzpatrick also sat on the FDA Blood Products Advisory Committee and the HHS Blood Safety and Availability Committee.

Richard Gonzales, MS, MT(ASCP)SBB

COL, USA, Ret.
President and CEO
Richblo2d Biologics Consulting Services LLC

Rich Gonzales, a native of San Antonio, Texas, received a Bachelor of Arts degree in Biology from St. Mary’s University in 1985, San Antonio Texas and dual Masters of Science degrees in Biology and Immunohematology from Bowling Green State University, Bowling Green, Ohio in 1993.  He received his commission as a second lieutenant in the Medical Service Corps and was a Distinguished Military Graduate. His varied military assignments include Platoon Leader, 2/8th Infantry, 4th Infantry; Chief of Blood Services at three Army Medical Centers; US Central Command Joint Blood Program Officer, Operation Enduring Freedom; Combat Developer, AMEDD Center and School; Assistant Professor of Military Science, Santa Clara University; and Advanced Development Product Manager for Blood Safety, US Army Medical Research and Material Command. His last assignment on active duty was as the Director of the Army Blood Program; and the Blood Bank Consultant to the Army Surgeon General, US Army Medical Command/ Office of the Surgeon General. He retired in 2015 with 30 years of service to the US Army.

After retirement, he was hired by TerumoBCT as Director of Grants Management and Government Sponsored Research and Principal Investigator, where in a three year period, he secured over $300M in federal grants and contracts. In 2018, He formed his own consulting company and now provides assistance to biotechnology firms and universities on funding opportunities and developing needed technologies.

He is a certified Medical Technologist and a Specialist in Blood Banking.  He has served as an Assessor with the American Association of Blood Banks, as well as an Inspector for the College of American Pathologists for over 25 years.

He is a graduate of the AMEDD Officer Basic and Advance Courses, U.S. Army Medical Logistics Management Course, U.S. Army Clinical Laboratory Officers Course, the US Army Blood Bank Fellowship Course, U.S. Army Combined Armed Services Staff School, the U.S Command and General Staff College, the Intermediate Medical Acquisition Course and the AMEDD Executive Skills Course. He completed Level 2 Acquisition training with the Defense Acquisition University. Some of his awards include the Legion of Merit, Bronze Star, Meritorious Service Medal with 6 OLC, the Expert Field Medical Badge, the Order of Military Medical Merit, the Army Surgeon General’s Proficiency skill identifier

COL (Ret) Gonzales has published numerous journal articles in peer reviewed journals, contributor to the 4th edition of the US Army War Surgery Handbook and is a noted national and international speaker on military blood banking and blood safety. COL (Ret) Gonzales served on a White House Task Force on Blood Support for National Disasters.

Raymond Goodrich, PhD

Executive Director, Infectious Disease Research Center
Office of the Vice President for Research
Professor, Department of Microbiology, Immunology and Pathology,
Colorado State University

As the Executive Director of the Infectious Disease Research Center (IDRC) at Colorado State University, Dr. Goodrich has responsibility for oversight of the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), the Regional Biocontainment Labs (RBL) and the Research Innovation Center (RIC). BioMARC is an FDA-inspected not-for-profit service entity that specializes in the production of biological products that require high containment facilities. The RBL facility houses BSL3, select agent and CDC Tier I agent based research programs and is part of the regional biocontainment laboratory network under the National Institute of Allergy and Infectious Diseases (NIAID). The RIC facility houses faculty and private industry research programs.

Dr. Goodrich formerly served as Vice President of Scientific and Clinical Affairs and Chief Scientific Officer, Blood Bank Technologies, for Terumo BCT, a leading global medical device manufacturer based in The United States. His responsibilities included oversight of research and development and clinical programs in the field of blood product processing and blood safety. He has worked in medical research for over 29 years during which he managed research staff and development programs in the fields of transfusion and transplantation medicine and pathogen reduction technologies. He has been awarded over 58 patents covering technology in these areas and has co-authored over 200 peer reviewed articles and abstracts. He has also served as the Principal Investigator for grants totaling over $40M from the United States Department of Defense (Congressionally Designated Medical Research Program) for the development of a transportable blood treatment system that is currently in routine use in locations around the world. He is a 2018 recipient of the Order of Military Medical Merit (O2M3) for his work on programs of importance to the US Army Medical Command.

Dr. Goodrich has also been the founder of 4 startup businesses with focus in biotechnology (CryoPharm), blood safety (Navigant Biotechnologies), cancer immunotherapy (PhotonPharma) and general product development and registration consulting services (Innovata BioConsulting).

John Holcomb, MD, FACS

COL, USA, Ret.
Professor of Surgery
University of Alabama

John Bradley Holcomb received his M.D. from the University of Arkansas Medical School in 1985. Dr. Holcomb entered the U.S. Army in 1985, and completed his general surgery training in 1991. Dr Holcomb then deployed with the Joint Special Operations Command for the next decade. From 2002 to 2008, COL Holcomb was the Commander of the U.S. Army Institute of Surgical Research and Trauma Consultant for the Army Surgeon General. Over the years he has deployed in multiple real world operations. He is a three time recipient of the Army’s Greatest Invention award. COL Holcomb retired from active duty in 2008 and received the Lifetime Achievement Award in Trauma Resuscitation Science from the American Heart Association, the United States Special Operations Command Medal, and the Service award from the American College of Surgery. He has been a member of the Committee on Tactical Combat Casualty Care since 2001. In 2008, Dr. Holcomb joined the University of Texas Health Science Center at Houston as a Professor of Surgery. In 2016 he received the MAJ Jonathan Letterman award from the National Museum of Civil War Medicine. Dr. Holcomb is actively involved in clinical medicine, education, research, entrepreneurship and is a founder of a small health IT company. He reviews papers for more than 25 journals, has published > 500 peer reviewed articles and serves on multiple boards. Dr. Holcomb and his wife, Dr. Kelly Wirfel, were married in 1998 and have 2 children.

Mary Homer, PhD

Chief United States Radiological and Nuclear Countermeasures, Division of Chemical, Biological, Radiological, and Nuclear Countermeasures
Biomedical Advanced Research and Development Authority (BARDA)

Keith Hoots, MD

Director, Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute

Dr. W. Keith Hoots became Director of NHLBI’s Division of Blood Diseases and Resources in 2009. Dr. Hoots received his A.B. in English and Chemistry and his M.D. from the University of North Carolina (UNC) in Chapel Hill, North Carolina.  He then completed his Pediatric Internship/Residency at Children’s Medical Center, Parkland Memorial Hospital in Dallas, Texas; then Fellowship in Pediatric Hematology Oncology at UNC.  He  was faculty at University of Texas M.D. Anderson and UT-Houston. Dr. Hoots’ major research interests have been congenital and acquired bleeding disorders and clotting disorders and disseminated intravascular coagulation (DIC), in particular DIC in head trauma.   He has a strong interest in global collaborations.

Dr. Hoots is a past member of the U.S.  Health and Human Services Blood Safety and Availability Advisory Committee to the Secretary of Health, past chair of the Medical and Scientific Advisory Committee for the National Hemophilia Foundation and subcommittee co-chair of the DIC Subcommittee of International Society of Thrombosis and Hemostasis.  He is a past president of the Hemophilia Research Society of North America.

Donald Jenkins, MD

Professor of Surgery Uniformed Services University
Professor/Clinical, Division of Trauma and Emergency Surgery
Vice Chair for Quality, Department of Surgery UT San Antonio
Betty and Bob Kelso Distinguished Chair in Burn and Trauma Surgery

Dr Donald Jenkins earned a BS in Biochemistry from the University of Scranton in Scranton PA and MD at the Uniformed Services University in Bethesda MD. He performed his surgical residency at Wilford Hall USAF hospital in San Antonio TX, trauma fellowship at the University of Pennsylvania in Philadelphia PA and retired after nearly 25 years of active duty service from the USAF in 2008.

Dr Jenkins was trauma medical director at Saint Marys Hospital at Mayo Clinic in Rochester, for the United States Air Force (2000-2008) at Wilford Hall, for the 44th Medical Command for all medical care in Iraq (2004-2005), helped to develop the Joint Theater Trauma System for the United States Central Command (all of southwest Asia), was the trauma director of the Joint Theater Trauma System (Baghdad Iraq and Bagram Afghanistan 2006), helped develop the Joint Trauma System and was the trauma medical director of the Joint Trauma System (Fort Sam Houston, TX 2007-2008). He is currently Professor of Surgery, Vice Chair for Quality and Associate Deputy Director of the Military Health Institute at the University of Texas Health Science Center in San Antonio

Lucy Kornblith, MD

Assistant Professor of Surgery
Trauma Surgery and Surgical Critical Care
University of California San Francisco
Zuckerberg San Francisco General Hospital

Lucy Zumwinkle Kornblith is an Assistant Professor of Surgery, Trauma Surgery and Surgical Critical Care at the University of California, San Francisco (UCSF) and Zuckerberg San Francisco General Hospital. She is a surgeon scientist in the translational study of coagulation and inflammation perturbations after trauma, and currently focuses on phenotyping post-injury platelet biology. She was awarded the Eastern Association for the Surgery of Trauma, Trauma Research Scholarship in 2018 and is now supported through 2023 by a Patient Oriented Mentored Career Development Award through the National Institute of General Medical Studies section of the NIH for her study of post-injury platelet biology. Dr. Kornblith is co-director of the research collaborative Trauma, Injury Science, and Critical Care Collaborative (TRISECCCT) at Zuckerberg San Francisco General Hospital, and as part of this has extensive experience in prospective observational studies and nuances of biospecimen collection in injured patients.

Rosemary Kozar, MD, PhD

Professor of Surgery
Vice Chair of Research
University of Maryland

Dr. Rosemary Kozar is currently Professor of Surgery and Director of Translational Research at the University of Maryland R Adams Cowley STC. She completed medical school at Temple University School of Medicine then surgical training and surgical critical care at the University of Texas Houston and Temple University while also obtaining a PhD at Baylor College of Medicine.  Her research interests are in nutrition in the critically ill and endothelial dysfunction after hemorrhagic shock. She has published over 180 peer-reviewed articles and has been continuously funded by the NIH for almost 20 years. She has also served on a number of NIH study sections. Dr. Kozar is active at the national level, having served as Chair of the Verification Committee for the American College of Surgeons, on the Board of Managers for the AAST and as Past President of the Shock Society. She is currently Secretary of Western Trauma Association and Chair of the National Trauma Institute.

Geoffrey Ling, MD, PhD

COL, USA, Ret.
Chief Executive Officer at SunQ, LLC
Ex Director and Founder of the Defense Advanced Research Projects Agency (DARPA) Biological Technologies Office

Geoffrey Ling, M.D., Ph.D., Col. (Ret.), is a clinician-scientist advancing technology as it pertains to improving the human condition. Additionally, he is Chief Executive Officer at SunQ, LLC. He serves as a Professor of Neurology and Neuroscience at the Uniformed Services University of the Health Sciences. Dr. Ling has been a Member of Scientific Advisory Board at BrainScope Company, Inc. since March 15, 2016. He is also an attending neurocritical care Physician at Johns Hopkins Hospital and is board certified in both neurology and neurocritical care. He previously served as the Founding Director of the Biological Technologies Office at the Defense Advanced Research Projects Agency (DARPA) and the Assistant Director for Medical Innovation of the Science Division at the White House Office of Science and Technology Policy. Dr. Ling has published over 180 peer-reviewed articles, review articles and book chapters and 1 patent. He is a retired US Army Colonel having retired after 21 years of active duty. He serves as an Advisory Board Member at Camden Partners Holdings, LLC. He is responsible to advice for seed strategy investments at the firm. Dr. Ling earned a B.A. degree from Washington University in Biology and History, a Ph.D. degree in Pharmacology from Cornell University and an M.D. degree from Georgetown University School of Medicine.

Clifford Lowell, MD, PhD

Professor and Distinguished Chairman Department of Laboratory Medicine, UCSF

Dr. Clifford Lowell, MD, PhD serves as a Professor and Chair Department of Laboratory Medicine, University of California, San Francisco. Dr. Lowell joined the faculty in the Dept. of Laboratory Medicine in 1995 and served as the Director of Clinical Immunology Laboratory through 2006. His group continues to work on a variety of aspects of tyrosine kinases and intracellular signaling in innate immune cells. Dr. Lowell is a standing member of the NIH Innate Immunity Study Section. In 2006, he was named Chairman of the Laboratory Medicine at UCSF with overall Departmental responsibility for Clinical Pathology, Transfusion Medicine and diagnostic testing at UCSF. Dr. Lowell serves as a Member of the Scientific Advisory Board of Linkage Biosciences, Inc. Dr. Lowell has authored over 110 peer-reviewed scientific manuscripts, received the prestigious Scholar Award from the Leukemia/ Lymphoma Society. He received his MD, PhD degrees from Johns Hopkins School of Medicine in 1986. Dr. Lowell completed his training in Internal Medicine at the Johns Hopkins Hospital in 1989 and subspecialty training in Hematology/Oncology at UCSF in 1993. His post-doctoral research fellowship training was done with Dr. Harold Varmus at UCSF from 1989 to 1995, where he developed his research interests in tyrosine kinase based signaling mechanisms.

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development.  He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Christophe Martinaud, MD

Professor of Transfusion Medicine and Cell Therapy
French Military Blood Institute Clamart

Lt.Col. Dr. Christophe Martinaud is a physician, specialist in laboratory medicine and a scientist whose researches are focused on hemorrhagic shock and mesenchymal stromal cells(MCs). He works as the head of the department of Clinical Operations (delivery of blood products, cells and tissues) and as director in the department of Advanced Therapy Medicinal Products and in the R&D Unit, at the French Military Blood Institute. He is in charge of mesenchymal stem cell production as the head of the department of ATMPs. These cells are routinely used for burns therapy and for research purposes. He works on French Lyophilized plasma and was the first to report data about its use in Afghanistan. He focused his research in this field on hemostatic properties, clinical trials in civilian and military settings and hemovigilance reporting. He also has a research activity focused on MSCs and their role in the pathogeny in hematological malignancies. His publishing activities are focused on military blood transfusion, massive bleeding, and also on hematology.

Aby J. Mathew, PhD

Senior VP & CTO
BioLife Solutions

Dr. Mathew was part of the founding team of BioLife Solutions, Inc., and is a co-developer of BioLife’s biopreservation media solutions. Dr. Mathew has been researching low temperature biopreservation since 1994, and his studies contributed to the development of BioLife’s current commercial HypoThermosol® and CryoStor® product platforms and intellectual property foundation. Dr. Mathew was BioLife’s first Director of Manufacturing, established BioLife’s initial Quality system, and is currently Senior Vice President & Chief Technology Officer.

Michael Matthay, MD

Professor of Pulmonary Critical Care Medicine
Associate Director of ICU
University of California San Francisco

Michael A. Matthay, MD is a Professor of Medicine and Anesthesia at the University of California at San and a Senior Associate at the Cardiovascular Research Institute. He is Associate Director of Critical Care Medicine. He received his AB from Harvard University in 1969 and his MD from the University of Pennsylvania School of Medicine in 1973. Dr. Matthay received clinical training in Internal Medicine at the University of Colorado from 1973-76 and in Pulmonary and Critical Care Medicine from the University of California at San Francisco from 1977-78. He also received research training from the Cardiovascular Physiology Laboratory, University of Colorado in 1976 and the Cardiovascular Research Institute from 1978-79. He is a former Chairman of the Respiration Section of the American Physiological Society and he served as a member (1995-2000) and chair (1998-2000) of the NIH Lung Biology and Pathology study section. He received an American Thoracic Society award for Scientific Achievement in 2002. He is a member of the American Association of Physicians. Dr. Matthay’s basic research is focused on active ion, solute, water, and protein transport mechanisms across the alveolar epithelium that account for the resolution of pulmonary edema. He has also studied the function of the alveolar epithelium under conditions of acute lung injury. The studies are carried out with both in vivo and in vitro models. Dr. Matthay’s clinical research is focused on the mechanisms that account for the pathogenesis and resolution of clinical acute lung injury and pulmonary edema. His most recent work has focused on the potential therapeutic value of mesenchymal stem cells for the treatment of acute lung injury and has recently completed a multi-center phase 1 trial and started a multicenter prospective phase 2 clinical trial for MSCs in ARDS.

Robert Mays, PhD

Vice President, Regenerative Medicine
Head of Neurosciences, Athersys, Inc.

Robert Mays received his Ph.D. in Molecular and Cellular Physiology at Stanford University where his research focused on the biological mechanisms determining protein sorting in polarized cells. After doing Post-doctoral research at the University of Utrecht in the Netherlands, the Weizmann Institute in Rehovot Israel and the University of California, San Francisco, Dr. Mays co-founded Athersys Inc., which focuses on developing novel and proprietary best-in-class therapies designed to extend and enhance the quality of human life. Currently, he is the Vice President of Regenerative Medicine and the Head of Neurosciences at Athersys and is focused on the company’s novel human adult stem cell product, MultiStem®, and its applications in Regenerative Medicine and drug discovery, with a specific focus on injuries and diseases affecting the central nervous system. Dr. Mays is a member of the National Center for Regenerative Medicine, Center for Stem Cell and Regenerative Medicine, the American Heart Association and is an Adjunct Professor at the Case Western Reserve University School of Medicine. He is currently the Principal Investigator of the FDA sanctioned Phase I/II clinical trial testing the safety and efficacy of MultiStem in treatment of patients who have suffered an acute ischemic stroke.

Owen McCarty, PhD

Professor and Chair of Department of Biomedical Engineering
Professor of Department of Cell & Development Biology
Oregon Health & Science University

The vascular system represents an exquisite feat of bioengineering. Fluid (blood) flow and mass transfer are intimately integrated with and actively regulate vascular cell responses. Therefore, elucidating the molecular nature of cellular processes in the dynamic setting of the vasculature requires the synthesis of engineering fundamentals with the tools of cell biology. My research is focused on understanding the interplay between cell biology and fluid mechanics in the cardiovascular system. My research into the balance between hydrodynamic shear forces and chemical adhesive interactions has great relevance to the underlying processes of cancer metastasis, cardiovascular disease, and inflammation. The goal of my research program is to develop molecular-targeted therapies to combat these disorders.

Jeffrey McCullough, MD

University of Minnesota

David McKenna, MD

Professor of Transfusion Medicine
Director of the Division of Transfusion Medicine
University of Minnesota

Dr. McKenna holds the American Red Cross Chair in Transfusion Medicine and is Director of the Division of Transfusion Medicine. He also serves as the Scientific and Medical Director of Molecular and Cellular Therapeutics (MCT), the University’s cGMP facility, as well as Laboratory and Medical Director of the University of Minnesota Medical Center Clinical Cell Therapy Laboratory and the director of the fellowship program in Transfusion Medicine/Blood Banking. McKenna is an active AABB member, serving on the board of directors for four years and leading the AABB Cellular Therapy Section Coordinating Committee for several years. He was a key investigator in the NIH-sponsored Production Assistance for Cellular Therapies contract from 2003-2015.

Ernest Moore, MD

Professor of Surgery
Vice Chair of Research
Editor of Journal of Trauma and Acute Care Surgery

Ernest E. “Gene” Moore, M.D. was the Chief of Trauma at the Denver General Hospital for 36 years, Chief of Surgery for 28 years, and the first Bruce M. Rockwell Distinguished Chair in Trauma Surgery.  He continues to serve as Vice Chairman for Research and is a Distinguished Professor of Surgery at the University of Colorado Denver (UCD), and has been the Editor of the Journal of Trauma since 2011.

Under Dr. Moore’s leadership, the Rocky Mountain Regional Trauma Center at Denver General became internationally recognized for innovative care of the injured patient, and its trauma research laboratory has been funded by the NIH for 30 consecutive years.  In July 2018, the center was renamed the Ernest E Moore Shock Trauma Center at Denver Health.

Dr. Moore has served as president of nine academic societies, including the Society of University Surgeons, American Association for the Surgery of Trauma, International Association for the Trauma and Surgical Intensive Care, and the World Society of Emergency Surgery; and as Vice President for the American Surgical Association.

His awards include the Robert Danis Prize from the Society of International Surgeons, Orazio Campione Prize from the World Society of Emergency Surgery, Philip Hench Award from the University of Pittsburgh, Florence Sabin Award from the University of Colorado, Lifetime Achievement Award from the Society of University Surgeons,  Lifetime Achievement Award for Resuscitation Science from the American Heart Association,  Distinguished Investigator Award from the American College of Critical Medicine,  Distinguished Investigator Award from the Shock Society, Lifetime Service Award from the International Association for Trauma and Surgical Intensive Care, and Medallion for Scientific Achievement from the American Surgical Association.  He has honorary fellowships in the Royal College of Surgeons of Edinburgh, the Royal College of Surgeons in Ireland, the Royal College of Surgeons of Thailand, and the American College of Emergency Physicians; and is an honorary member of the Brazilian Trauma Society, Colombian Trauma Society, Eastern Association for the Surgery of Trauma, European Society for Trauma and Emergency Surgery, North Pacific Surgical Association, and Trauma Association of Canada. Dr. Moore is coeditor of the textbook Trauma, in its 9th edition, Surgical Secrets in its 7th edition, and Trauma Induced Coagulopathy, in its 2nd edition; he has >1700 publications and has lectured extensively throughout the world.

He is married to Sarah Van Duzer Moore, M.D., an internist at the University of Colorado Denver, and they have two sons; Hunter, a transplant fellow at UCD and Peter, a pulmonary/critical care fellow, both at UCD. Dr. Moore’s additional interests include endurance sports, mountaineering, skiing, and wapiti pursuit. He lives by the principle to work hard you must play hard, with the understanding that family is the ultimate priority.

Christopher Murphy

M SGT, USA, Ret.
CEO Combat Medical Solutions

Matthew Neal, MD

Roberta G. Simmons Assistant Professor of Surgery
Assistant Professor of Clinical and Translational Science and Critical Care Medicine
University of Pittsburgh

Dr. Neal is the Roberta G. Simmons Assistant Professor of Surgery and an attending surgeon in the Division of Trauma and Acute Care Surgery at the University of Pittsburgh. He holds secondary appointments in the Departments of Critical Care Medicine, the Vascular Medicine Institute (VMI), and the Clinical and Translational Science Institute (CTSI) at the University of Pittsburgh. Dr. Neal runs a translational research program focused on hemostasis and thrombosis following injury, and his laboratory is funded by multiple awards from the NIH (including a Maximizing Investigators Research Award (MIRA) from NIGMS) as well as the Department of Defense. He is PI or Co-I on a number of ongoing clinical trials in trauma and surgical pre-habilitation, and he serves as the Co-Director of the Pittsburgh Trauma Research Center.

Paul Ness, MD

Senior Director, Division of Transfusion Medicine
Professor of Pathology
Johns Hopkins University

Dr. Paul Ness is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine. His area of clinical expertise includes transfusion support of hematology and oncology patients, autoimmune hematologic disorders, and massive transfusion protocols.  Dr. Ness served as the director of the Division of Transfusion Medicine and program director of the Blood Banking/Transfusion Medicine Fellowship Program in the Department of Pathology for 38 years before relinquishing these responsibilities in 2017.

Dr. Ness has an extensive background in clinical transfusion medicine and research activities related to blood safety. He was a co-investigator with Dr. Kenrad Nelson on the FACTS study, which followed cardiac surgery patients to determine their risk of seroconversion to viral agents such as HIV and hepatitis. He is a consultant on the REDS III program for the National Heart, Lung, and Blood Institute. Along with Dr. Hua Shan, he is PI of the China project for the international REDS III program. He has also conducted a major study documenting the risk of bacterial contamination of platelets, and was the PI for the Johns Hopkins site in the NHLBI Transfusion Medicine Hemostasis Clinical Trial Network.

He has extensive experience in blood safety education programs internationally. He has worked with Drs. Shan and Nelson to teach blood safety in China, India and Laos/Thailand through the Hopkins Fogarty program. Additionally, he has had extensive teaching roles in Vietnam, India, Egypt and Africa.

Dr. Ness received his undergraduate degree from the Massachusetts Institute of Technology. He earned his M.D. from State University of New York at Buffalo. He completed his residency at The Johns Hopkins Hospital and performed a fellowship in oncology at the University of California, San Francisco.

His research interests include transfusion medicine, immune hemolysis and transfusion alternatives.

He was editor of Transfusion for 15 years and a past president of the American Association of Blood Banks.

Jan Nolta, PhD

Director, Stem Cell Program and Institute for Regenerative Cures
University of California Davis Health
Scientific Director, UC Davis GMP Facility
Editor-in-Chief, Stem Cells

Dr. Nolta is the Director of the Stem Cell Program at UC Davis School of Medicine, and directs the new Institute for Regenerative Cures. The UC Davis stem cell program has over 145 faculty members collaborating to work toward stem cell-related cures for a spectrum of diseases and injuries. The current research in Dr. Nolta’s laboratory is focused on developing therapies that will use mesenchymal stem cells (MSCs) to deliver factors for treating Huntington’s disease and other disorders and injuries. Her group focuses on “bench to the bedside” research, and she has been involved in numerous clinical trials of gene and cell therapy. She is scientific director of the new Good Manufacturing Practice clean room facility at UC Davis, where stem cells of different types are being isolated or expanded for clinical trials.

Terry Opgenorth, PhD

Vice President & Director of Launchpad
Colorado State University Ventures

Terry Opgenorth, Ph.D., serves as VP and Exec Director of LAUNCHPAD for CSU Ventures. He previously was VP of Metabolic Disease, Antiviral and Target-Lead Discovery Research for Abbott Laboratories (now AbbVie).  He also served as CEO, Vidasym.  In his biopharma career, he built and led teams that advanced 13 human and 2 animal drug candidates into clinical development for cardiovascular, cancer, anti-viral and metabolic disease indications, yielding 3 on-market drugs.  Terry holds other positions, including CSO/Founder of VetDC, and Director at KromaTiD, VetDC, and UNeMed.  He previously served as Founder/Advisor to Colorado Center for Drug Discovery (C2D2), and Board Director for Colorado Institute for Drug, Device, and Diagnostic Development, Colorado Bioscience Association, and Keystone Symposia.  Dr. Opgenorth holds a B.A. in Biology from Calvin College and M.S. and Ph.D. degrees in Physiology from University of Illinois-Urbana.

Biju Parekkadan, PhD

Associate Professor, Biomedical Engineering, Rutgers University
Division Leader, Center for Surgery, Innovation, and Bioengineering, Harvard Medical School and Massachusetts General Hospital
Affiliated Faculty, Harvard Stem Cell Institute and the Broad Institute for Genetics
Co-Founder, Director, and Office of Chief Scientific Officer, Sentien Biotechnologies, Inc.

Dr. Parekkadan is an Associate Professor of Biomedical Engineering with a laboratory that specializes in cell and genetic engineering. He has experience in developing biotech products as a founder of Sentien, a clinical stage pioneer of ex vivo cell therapeutics, as well as advising several companies as a founding member of CellOne Partners. Dr. Parekkadan received his PhD in Chemical and Medical Engineering from the Harvard-MIT Division of Health Sciences and Technology, where he also completed all MD studies. His efforts have been recognized through notable awards including being named Young Mentor of the Year by Harvard Medical School and a Presidential Early Career Scientist from the Office of the White House, the highest honor of an early stage investigator.

Shibani Pati, MD, PhD

CTTACC Conference Chair
Professor of Laboratory Medicine, UCSF
Scientific Director of Cellular Therapies

Dr. Pati is currently at employed at UCSF in San Francisco California. She is the Associate Professor and Scientific Director of Cellular Therapies at the University of California San Francisco (UCSF) -Department of Laboratory Medicine. She is by training a cancer vascular biologist with an interest in the role of endothelial dysfunction and vascular compromise in the pathogenesis of human disease- specifically trauma and traumatic brain injury (TBI). Dr. Pati received her MD. PhD. from the University of Maryland and completed a post-doctoral fellowship in Physical Medicine and Rehabilitation at the Baylor College of Medicine and the University of Texas in Houston. Following her fellowship, Dr. Pati worked at the Center for Translational Injury Research (CeTIR) at the University of Texas Houston. Dr. Pati’s specific areas of investigation involve the use of stem cells, blood products and novel resuscitative modalities that can mitigate endothelial dysfunction, inflammation and coagulation disturbances found in traumatic injury. Her lab aims to specifically understand the mechanisms of vascular compromise in injury and novel methods by which to modulate it. Recent studies by Dr. Pati have involved the mechanisms of action of mesenchymal stem cells in TBI, and trauma and hemorrhage.

Heather Pidcoke, MD, PhD

Chief Medical Research Officer
Associate Director, Research
Translational Medicine Institute
Colorado State University

Heather Pidcoke, MD, MSCI, PhD, is Chief Medical Research Officer for the Colorado State University (CSU) campus and Associate Director of Research for CSU’s Translational Medicine Institute (TMI). Dr. Pidcoke’s research interests include trauma, critical care, and novel transfusion products/ biologics for the resuscitation of massively bleeding patients in austere environments. Prior to joining the TMI, Dr. Pidcoke was Chief Medical Officer for Cellphire, Inc., a biotechnology company developing a lyophilized platelet-derived hemostatic agent. Dr. Pidcoke served as Director, Global Translational Affairs at Terumo BCT where she was the Principle Investigator for four major novel blood product development efforts funded by BARDA, DoD, and CDRMRP. Early in her career, Dr. Pidcoke worked for the United States Army Institute of Surgical Research (USAISR) as a research physiologist and deputy chief of the Blood and Coagulation Research group. She was awarded a U.S. Army Commander’s Award for Civilian Service in recognition of her contributions in advancing medical research for military personnel, and the Presidential Early Career Award for Scientists and Engineers from the United States White House Office of Science and Technology Policy.

Mark Popovsky, MD

Chief Medical Officer
Velico Medical, Inc

Mark Popovsky is an honors graduate of the University of Vermont College of Medicine. He completed his residency at the NIH and took his fellowship in Transfusion Medicine at the Mayo Clinic. He served as the director of Transfusion and Intravenous Services at Mayo, before taking joint positions at Beth Israel Hospital in Boston and Harvard Medical School. Concurrently, he was the Chief Medical Officer and Chief Executive Officer at New England Region of the American Red Cross. He left the Red Cross to become the Chief Medical Officer at the Haemonetics Corporation. He has published more than 400 peer-reviewed articles and edited or published 5 books in transfusion medicine.  He has served in Nigeria on a PEPFAR mission and numerous WHO missions to Central America.  He has received numerous awards for contributions to transfusion medicine and teaching. He is currently the Chief Medical Officer of Velico Medical as well as Chief Safety Officer of Haemonetics Corporation.

Joseph Rappold, MD

Professor of Surgery
Maine Medical Center Tufts University

Dr Rappold is an Alpha Omega Alpha graduate of the Temple University School of Medicine in Philadelphia, Pennsylvania. Prior to entering medical school he completed 7 years as a US Navy nuclear submarine officer serving on a variety of submarines. His surgical residency was completed at the Naval Medical Center San Diego and his fellowship was completed at the University of California San Diego. He then commenced a series of six combat deployments to both Iraq and Afghanistan commanding a variety of facilities including all US personnel at the British Field Hospital at Camp Bastion. He also served as the Central Command’s Theater Trauma Director responsible for all trauma services and surgical care in both Iraq and Afghanistan. In San Diego he directed the SICU and eventually became chair of the Department of Surgery at the military’s largest medical facility. He retired from the US Navy after 30 years of active duty service. He is currently the Chief of Acute Care Surgery and the Trauma Medical Director at Maine Medical Center. He has published multiple articles and book chapters and has received a variety of unit and personal awards including the Bronze Star for valor in combat and the Defense Meritorious Service Medal.

Ephron Rosenzweig, PhD

Assistant Professor of Neurosciences
Center for Neural Repair
University of California San Diego

Since 2005, I have directed the Primate SCI Research Project at the Center for Neural Repair at UCSD. Much of my research is part of the California Spinal Cord Injury Consortium, a group composed of researchers from UCSD, UCLA, UCSF, UC Irvine, UC Davis, Colorado State University, and Switzerland’s Ecole Polytechnique Federale de Lausanne. Drawing only the most promising candidate treatments from research in rodent models of SCI, we examine the neuroanatomical, electrophysiological, and functional efficacies of those treatments in animal models that better reproduce the conditions of human SCI. My main current focus is on the formation of long-distance neuronal relays using neural stem cells transplanted into SCI lesions. Additional studies are underway to evaluate the efficacy of enzymatic degradation of inhibitory chondroitin sulfate proteoglycans (CSPGs).

Jon Rowley, PhD

Chief Executive & Technology Officer, RoosterBio, Inc.

Dr. Rowley founded RoosterBio as part of his personal quest to significantly improve commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 30 peer reviewed manuscripts and 15 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy. Prior to RoosterBio, Jon created innovative products at BD, Aastrom Bioscience, and most recently, was Director of Innovation and Process Development at Lonza’s Cell Therapy CMO business. Jon resides in Walkersville, MD with his wonderful wife and three young children.

Jürgen Schmitz, PhD

Chief Scientific Officer
Miltenyi Biotec

Jürgen Schmitz serves as the Chief Scientific Officer at Miltenyi Biotec in Bergisch Gladbach, Germany. He is part of the management board. Before joining the company in 1994, he started his scientific career at the Institute of Genetics, University of Cologne, where he wrote his diploma thesis and his PhD thesis under the supervision of Prof. Dr. Andreas Radbruch. He acquired a broad expertise in immunology including cellular and humoral immunology, which he constantly expanded. Today, he supervises a highly interdisciplinary team of about 350 employees, covering an entire spectrum of activities from basic research to applied research to product development. Cell-based therapies have always been at the forefront of his activities at Miltenyi Biotec. Jürgen Schmitz is member of the American Society of Hematology (ASH), the American Association of Immunologists (AAI), the American Association for Cancer Research (AACR), the American Society of Gene & Cell Therapy (ASGCT) and the International Society for Stem Cell Research (ISSCR).

Martin Schreiber, MD

CTTACC Conference Co-Chair
Professor of Surgery & Chief of Trauma, Critical Care & Acute Care Surgery
Oregon Health & Science University (OHSU)

Dr. Martin Schreiber is Chief of Trauma, Critical Care and Acute Care Surgery at Oregon Health & Science University. He is the chief of Region 10 of the American College of Surgeons Regional Committees on Trauma and as such he supervises the ACS Committees in Alaska, Washington, Oregon and Idaho.  He has been deployed to Iraq and Afghanistan and he has served as the Joint Theater Trauma System Director. Dr. Schreiber is also the director of the Trauma Research Laboratory at OHSU.   The Trauma Research Lab has been continuously funded by federal sources since 2001. Lab research interests include resuscitation of hemorrhagic shock, hemorrhage control and development of novel blood products. Current funding sources include the NIH, US Army, US Air Force and private industry. The lab is engaged in over 30 investigational protocols at OHSU. Dr. Schreiber is considered a leader in the trauma community and he has been an invited speaker throughout the United States and around the world.

Jim Sergi

President of CSSi LifeSciences

Jim Sergi is President of CSSi LifeSciences, a global drug discovery and technology development company providing fully integrated, specialized regulatory and clinical services for pharmaceutical and medical device companies. Prior to this role, Jim held various positions in academic oncology and cancer research before co-founding ProED, a healthcare services and drug development company. Jim has been responsible for over 100 successful NDA/BLA submissions and over 250 medical device approvals. His academic and medical experience includes Director for the Department of Experimental Therapeutics at the Cleveland Clinic Cancer Center, Associate Professor of Medical-Surgical Nursing at the Case Western Reserve University and Lecturer for Oncology at Cleveland State University. He has authored over 50 peer reviewed publications and has numerous issued patents. Jim serves a scientific reviewer for the NIH SBIR/STTR Commercial Readiness Program, as well as a mentor to the NIH/NHLBI and the NIH Larta FeedForward programs. He also serves as a member of the Global Center for Health Innovation and the NoCoBio Task Forces, and as a scientific advisor to numerous private equity and venture backed investment firms.

Stacey Shackleford, MD

Chief, Joint Trauma System Defense Center of Excellence for Trauma
US Army Institute of Surgical Research

Colonel Stacy Shackelford is the Chief, Joint Trauma System Defense Center of Excellence for Trauma, Joint Base San Antonio and practices as an attending trauma surgeon at San Antonio Military Medical Center.

Col Shackelford was commissioned through the U.S. Air Force Academy in 1989 and attended medical school at Tulane University and general surgery residency at the University of Utah. She completed two overseas tours as chief of General Surgery in Misawa, Japan and Lakenheath, England, as well as stateside assignments at Hill AFB, UT and Travis AFB, CA.
After completing a Trauma and Critical Care fellowship at the University of Southern California, Col Shackelford was assigned as Director of Education at the Air Force Center for Sustainment of Trauma and Readiness Skills at the R. Adams Cowley Shock Trauma Center in Baltimore, Maryland where she conducted pre-deployment trauma skills training for Air Force medics, nurses, and physicians. She has deployed five times as a combat surgeon and also served as the forward director of the United States Joint Theater Trauma System in 2012. She is currently the Chair of the Committee on Surgical Combat Casualty Care and a member of the Committee on Tactical Combat Casualty Care.

Beth Shaz, MD

President AABB
Chief Medical and Scientific Officer
Senior Vice President at New York Blood Center

Beth H. Shaz, MD, is the current President of AABB and the Chief Medical and Scientific Officer, Senior Vice President at New York Blood Center, and Adjunct Assistant Professor, Department of Pathology and Cell Biology, Columbia University Medical Center. Beth is leading NYBC’s recently launched Comprehensive Cell Solutions. CCS is focused on developing, improving, and implementing regenerative medicine, cell therapies, transfusion medicine, and related scientific and medical endeavors. She is also responsible for all medical and scientific activities at NYBC, including the Lindsey F. Kimball Research Institute, hemophilia services, transfusion services, cellular therapy, perioperative autologous transfusion, and clinical apheresis. Previously, she was an Associate Professor at Emory University School of Medicine and director of the transfusion service at Grady Memorial Hospital. Also, she was an instructor at Harvard Medical School and associate director of the transfusion service at Beth Israel Deaconess Medical Center in Boston. Beth received her Medical Degree with research distinction from the University of Michigan and Bachelor of Science in chemical engineering with distinction from Cornell University. She did a general surgery internship at Georgetown University, an anatomic & clinical pathology residency at Beth Israel Deaconess Medical Center, and a transfusion medicine fellowship at Harvard Medical School.

Jason Sperry, MD, MPH

Professor of Surgery and Critical Care
Director of Acute Care Surgery Fellowship
University of Pittsburgh

Dr. Sperry is a Professor with a primary appointment in the Department of Surgery, Division of Trauma and General Surgery and secondary appointments in the Department of Critical Care Medicine and the Clinical and Translational Science Institute (CTSI) at the University of Pittsburgh.He is a physician trained in general surgery and surgical critical care with a masters’ degree in public health. Dr. Sperry’s research focuses on the elucidation of the mechanisms that are responsible for sex-based outcome differences following injury, clinical outcomes following traumatic injury (primarily on massive transfusion), prehospital resuscitation, early correction of the coagulopathy that complicates injury, and the ability to predict a complicated post-injury course in the early prehospital and trauma bay setting. He is the principal investigator (PI) for the Linking Investigations Trauma and Emergency Services (LITES) network funded by the U.S. Department of Defense and PI of the PAMPer trial and STAAMP trials funded by the Prehospital Use of Plasma in Traumatic Hemorrhage (PUPTH) program and the Tranexamic Acid Clinical Research (TACR) program, under the direction of the Department of the Army.He is a co-investigator for the Trans-Agency Research Consortium for Trauma-Induced Coagulopathy (TACTIC) funded thru NHLBI, as well as multiple other NIH-funded grants. His overarching goal is to improve outcomes following traumatic injury.

Deborah Stein, MD

Professor and Chief of Surgery
Zuckerberg San Francisco General,
Vice Chair of Trauma and Critical Care Surgery
UCSF Department of Surgery

Deborah M. Stein, MD, MPH, earned her Bachelor of Arts degree from Cornell University, her Medical Degree from Albert Einstein College of Medicine and her Master of Public Health from Johns Hopkins University Bloomberg School of Public Health with certificates in both Injury Control and Health Policy. She completed her general surgery residency at Long Island Jewish Medical Center, Albert Einstein College of Medicine and a fellowship in Trauma/Surgical Critical Care at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center. She is a fellow in the American College of Surgeons and the American College of Critical Care Medicine.

Dr. Stein is certified by the American Board of Surgery in General Surgery with subspecialty certification in Surgical Critical Care. She has also earned subspecialty certification from the United Council for Neurologic Subspecialties in Neurocritical Care.

Upon completion of her fellowship in 2004, Dr. Stein joined the faculty at the University of Maryland School of Medicine where she served as the R Adams Cowley Professor in Shock and Trauma and Medical Director for Neurotrauma Critical Care, Medical Director for the Trauma Resuscitation Unit, Co-Director of the Neurotrauma Center for the State of Maryland, and as the Chief of Trauma at the R Adams Cowley Shock Trauma Center. Dr. Stein left Maryland and came to UCSF in 2019 to join the faculty in the Department of Surgery as Professor and Chief of Surgery at the Zuckerberg San Francisco General Hospital and Trauma Center.

Dr. Stein currently serves as Principal Investigator or Co-Principal Investigator on 4 federally funded grants and has authored nearly 200 peer-reviewed articles and more than 25 book chapters. Her national service includes active participation in major trauma, critical care, and surgical societies including serving as Secretary, Executive Board Member and member of the Board of Directors for the Eastern Association for the Surgery of Trauma.

Dr. Stein serves as Chair of the Research Committee and Member of the EMS, TQIP and Membership Committees for the American College of Surgeons’ Committee on Trauma. She serves as Chair of the Geriatric Trauma/ACS Committee for the American Association for the Surgery of Trauma and is a Member of the Scholarship Committee for the American College of Surgeons. She also serves on the Editorial Board for the Journal of Trauma and Acute Care Surgery and is an Examination Consultant for the Board of Surgery.

Dave Stroncek, MD

Chief of Cell Processing
National Institutes of Health

David Stroncek, MD, is the Director of the Center for Cellular Engineering (CCE) at the NIH Clinical Center. The CCE is a comprehensive facility that develops and manufactures a wide range of cell and gene therapies for phase 1 and 2 clinical trials. The CCE is currently manufacturing CAR T cells, lymphocyte engineered to express cancer associated antigen specific TCRs, dendritic cells, NK cells and genetically modified hematopoietic stems cells. The CCE has developed and is validating a GMP method to produce autologous induced pluripotent stem (iPS) cells from blood and to differentiate the iPS cells into retinal pigment epithelial cells.  The CCE also processes hematopoietic stem cells for transplantation. Dr. Stroncek’s research is focused on investigating new measures of cell and gene therapy quality and potency and developing new manufacturing methods to improve the consistency and quality of cell and gene therapies cells.

Jonathan Thon, PhD

Co-Founder and Chief Scientific Officer of Platelet BioGenesis

Jonathan Thon, Ph.D., is the co-founder, CEO and Chief Scientific Officer of Platelet BioGenesis. Dr. Thon is a leader in platelet science and has published more than 30 peer-reviewed articles on platelet production and storage. Prior to co-founding Platelet BioGenesis he was an assistant professor at Harvard Medical School and ran his own lab at Brigham and Women’s Hospital in Boston, where he retains an academic appointment. He earned his Ph.D. in biochemistry and molecular biology at the University of British Columbia, Vancouver.

Fabio Triolo, D.d.R., M.Phil., PhD

Associate Professor of Clinical and Translational Sciences
Director, Cellular Therapy Core
Department of Pediatric Surgery
McGovern Medical School at UTHealth

Fabio Triolo, D.d.R., M.Phil., Ph.D. is an expert in clinical cell therapy manufacturing, has a broad background in aseptic methods of harvesting, purification, processing, culture, storage and characterization of human cells, and extensive experience in compliance with current Good Manufacturing Practices (cGMP). He graduated summa cum laude in Biological Sciences from the University of Palermo, Italy, where he also completed a Research Doctorate (D.d.R.) in Chemical Sciences in 1999 and obtained the Italian Biological Board License in 2001. From 1996 to 2001 he was a Fulbright Fellow at Mount Sinai School of Medicine of New York University, where he was conferred a Master of Philosophy (M.Phil.) and a Doctor of Philosophy (Ph.D.) in Biomedical Sciences in 2000 and 2002, respectively.

In 2011, he joined the University of Texas Health Science Center at Houston (UTHealth) as Assistant Professor in the Department of Pediatric Surgery, Assistant Professor of Clinical and Translational Sciences and Director of the Human Cell Processing cGMP Facilities in the Program of Regenerative Medicine. He was promoted to Associate Professor in 2014. At the time of his recruitment, UTHealth did not have in-house clinical stem cell production capability and was dependent on the availability and expertise of external stem cell manufacturing establishments, in order to carry out cell therapy-based clinical trials. Dr. Triolo was recruited with the primary focus of reversing such trend by establishing a FDA-compliant biomanufacturing program at UTHealth. Accordingly, he established, made operational and directs the Cellular Therapy Core (CTC), which consists of The Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory and The Judith R. Hoffberger Cellular Therapeutics Laboratory, two FDA-registered cleanroom facilities where tissues and organs are processed to produce cell-based, tissue-based and combination products for clinical applications in compliance with cGMP of the FDA. Today, thanks to the CTC, UTHealth has an active and growing biomanufacturing program with a sophisticated translational facility that is actively manufacturing for multiple cell therapy trials. In May 2017, a bioartificial esophagus produced by Dr. Triolo’s team, the first clinical grade tissue engineered product ever manufactured at the University of Texas, was successfully implanted in man, for the first time in the world. Dr. Triolo’s most recent research interests also include the development of innovative autologous tissue engineering applications based on adult (e.g., adipose) and extra-embryonic (e.g., Amniotic Fluid, Wharton’s Jelly) tissues.

Alpa Mahuvakar Trivedi, PhD

Research Professor
Department of Laboratory Medicine, UCSF

Dr. Alpa Mahuvakar Trivedi is a Research Professor in the Department of Laboratory medicine at UCSF. She has conducted research in the field of trauma and neurotrauma for the last 18 years and has been actively involved in traumatic brain injury (TBI) and spinal cord injury (SCI) models in both rats and mice. Her research efforts have focused on developing cell based therapies in CNS models and assessing functional recovery. Her other focus area is the role of inflammation and specifically neutrophils and their granular content in disease progression.

Daniel Weiss, MD, PhD

Professor of Medicine
University of Vermont
ISCT Chief Scientific Officer

Dr. Weiss has a longstanding interest in lung repair and regeneration after injury, notably gene and cell therapy approaches for lung diseases. In particular this has included developing novel techniques with which to investigate and enhance lung gene and cell therapies. Recent published work in cell therapy approaches for lung diseases has included several benchmark publications that have included the first ever trial of cell therapy for COPD and that have helped define whether exogenous cells can engraft in the lung.  As such, he’s viewed as a translational scientist whose work spans from benchtop to clinical trials. He has also instituted a biennial meeting held at the University of Vermont, Stem Cells and Cell Therapies in Lung Biology and Diseases, that is widely viewed by the NIH, FDA, and non-profit Respiratory Disease Foundations as the major meeting in the field.  His overall goal is to provide a firm scientific basis for clinical application of cell therapies in lung diseases.  Dr. Weiss has been funded by the NIH, DOD, non-profit Respiratory Disease Foundations, and by industry sources since 1995.  His current work in the laboratory is focused in three major areas: 1) Bioengineering approaches for development of functional lung tissue ex vivo; 2) Immunomodulation of lung inflammation by mesenchymal stromal cells (MSCs); 3) Development of cell therapy-based approaches for lung disease.

Joseph C. Wu, MD, PhD

Director, Stanford Cardiovascular Institute Simon H. Stertzer, MD
Professor of Medicine & Radiology Stanford University School of Medicine

Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer, MD, Professor of Medicine and Radiology at the Stanford School of Medicine.

Dr. Wu has published 350 manuscripts. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients.

Dr. Wu currently serves on the Scientific Advisory Board for the Keystone Symposia (2014-2020), FDA Cellular, Tissue, and Gene Therapies Advisory Committee (2017-2020), AHA National Board of Directors (2017-2021), Chair of the AHA Basic Cardiovascular Science Council (2018-2020), and Chair of the AHA National Research Committee (2017-2021).

Joy Wu, MD

Assistant Professor of Medicine
Co Director Translational Investigator Program
Stanford University

Joy Wu is an Assistant Professor at Stanford, where she directs a basic and translational research program that focuses on skeletal development, the bone marrow hematopoietic niche, and stem cell therapies for bone. Dr. Wu has a clinical practice in the Stanford Osteoporosis and Metabolic Bone Disease Clinic, and is Co-Director of the Stanford Internal Medicine Translational Investigator Program. She earned her M.D. and Ph.D. degrees at Duke University, followed by Internal Medicine residency at Brigham and Women’s Hospital, and Endocrinology clinical fellowship at Massachusetts General Hospital. She was a recipient of the NIH Director’s New Innovator Award, and has received funding from the Mary Kay Foundation, Department of Defense, NIAMS, NIDDK, NHLBI, and NIA. Dr. Wu has served on the Board of Directors of Advances in Mineral Metabolism and was recently elected to the Board of Directors of the Endocrine Society.

Zafiris Zafirelis

Chief Executive Officer, Hemoglobin Oxygen Therapeutics LLC

Zaf Zafirelis, is the Chief Executive Officer and Co-Founder of Hemoglobin Oxygen Therapeutics (HbO2) a biotechnology focused developing hemoglobin-based oxygen carrier solutions for prehospital resuscitation of victims of trauma, severe acute anemia for situations when blood transfusions are not an option, reconditioning and viability evaluation of donor organs prior to transplantation, and several other related indications. Mr. Zafirelis, with more than 25 years of CEO experience, begun his career at American Cyanamid/Lederle Laboratories and is a 40 veteran of the pharmaceutical, medical device, and biotech industries. While at Biopure he led development of Oxyglobin, the only FDA and EMA approved hemoglobin-based oxygen carrier indicated for the treatment of canine anemia. Oxyglobin has been used to treat more than 125,000 animals worldwide including 30 different species including dogs, cats, horses, rhinos, tigers, birds and sharks. After leaving Biopure in 1995, he was co-founder and CEO of Cardiac Assist Technologies. While there he was the lead inventor of TandemHeart, a left atrial-tofemoral bypass ventricular assist device. In 2004, Zaf rejoined Biopure, this time as CEO, and has been associated with the technology through the company’s sale to OPK Biotech and subsequent acquisition of the assets by Hemoglobin Oxygen Therapeutics. He has been instrumental and remains extensively involved in the company’s expanded access program to provide product to hospitals treating patients for whom blood transfusions are not a option, as well as in establishing research collaborations for development of new indications with leading US, Canadian and EU academic institutions. Mr. Zafirelis holds an MS and an MBA (University of Southern California).

Presented by the University of California San Francisco Department of Laboratory Medicine


Questions? Email us at info@cttacc.org or call 303-238-0685